Meeting
2019 Genitourinary Cancers Symposium
Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance.
Authors
Guangxi Sun
West China Hospital, Chengdu, China
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 634)
DOI
10.1200/JCO.2019.37.7_suppl.634
Abstract #
634
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
A dual drug therapy for sunitinib resistant RCC: An in vitro analysis.
First Author: Jacob W. Greenberg
Poster
2012 Genitourinary Cancers Symposium
Treatment and overall survival (OS) in metastatic renal cell carcinoma (mRCC): A Swedish population-based study (2000-2008).
First Author: Ulrika Harmenberg
Poster
2024 ASCO Genitourinary Cancers Symposium
Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.
First Author: Marine Gross-Goupil
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world metastatic renal cell carcinoma (mRCC) treatment trends in Mexico: A public vs private sector analysis.
First Author: Iván Romarico González Espinoza